Author

Y. R. Cao

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7 Biochemistry· 1 Biophysics· 1 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 9 Approach:experimental assay· 8 Assay:proteomics· 6 Organism:human· 5 Organism:virus· 5 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Approach:comparative / phylogenetic analysis· 1

Frequent Co-Authors

Y. Wang· 9 shared F. Jian· 7 shared W. Song· 7 shared A. Yisimayi· 6 shared F. Shao· 6 shared R. Jin· 6 shared T. Xiao· 6 shared J. Wang· 5 shared

Activity by Year

2021-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersImmunology

Y. Wang

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Distinct SARS-CoV-2 populational immune backgrounds induce divergent RBD evolutionary preferences

W. Ma, H. Fu, F. Jian, Y. R. Cao, M. Li

The paper compares SARS-CoV-2 variants from China and other countries, finding that Chinese variants have more dispersed RBD mutations with higher ACE2 binding and less immune evasion potential due to a distinct immune background.

bioRxiv · Dec 19, 2023 · PreprintEvolutionary Biology

Antigenicity and infectivity characterization of SARS-CoV-2 BA.2.86

S. Yang, Y. Yu, F. Jian, W. Song, A. Yisimayi, X. Chen, Y. Xu, P. Wang, L. Yu, J. Wang, X. Niu, J. Wang, T. Xiao, R. An, Y. Wang, , Y. R. Cao

This study characterizes the antigenic properties and infectivity of the SARS-CoV-2 BA.2.86 variant, finding it evades immune responses but has reduced infectivity compared to previous variants.

bioRxiv · Sep 1, 2023 · PreprintImmunology

Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding

F. Jian, L. Feng, S. Yang, Y. Yu, L. Wang, W. Song, A. Yisimayi, X. Chen, Y. Xu, P. Wang, L. Yu, J. Wang, L. Liu, X. Niu, J. Wang, , Y. R. Cao

This study shows that convergent evolution of SARS-CoV-2 XBB lineages at RBD positions 455-456 synergistically enhances antibody evasion and ACE2 binding through epistatic interactions.

bioRxiv · Aug 30, 2023Immunology

Enhanced transmissibility of XBB.1.5 is contributed by both strong ACE2 binding and antibody evasion

C. Yue, W. Song, L. Wang, F. Jian, X. Chen, F. Gao, Z. Shen, Y. Wang, X. Wang, Y. R. Cao

This study shows XBB.1.5 has higher ACE2 binding and moderate antibody evasion, contributing to its increased transmissibility compared to other variants.

The Lancet Infectious Diseases · Mar 1, 2023Peer-reviewedImmunology

Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection

X. Chen, Y. Xu, Y. Xie, W. Song, Y. Hu, A. Yisimayi, F. Shao, L. Geng, Y. Wang, H. Gao, Y. Shi, S. Zhang, R. Jin, Z. Shen, Y. R. Cao

The paper assesses the protective effect of neutralizing antibodies from prior Omicron BA.5 infection against symptomatic reinfection with BA.5, BF.7, CH.1.1, and XBB.1.5 subvariants, finding a strong correlation between antibody titers and reduced reinfection risk.

bioRxiv · Feb 14, 2023Immunology

Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents

Y. R. Cao, F. Jian, Z. Zhang, A. Yisimayi, X. Hao, L. Bao, F. Yuan, Y. Yu, S. Du, J. Wang, T. Xiao, W. Song, Y. Zhang, P. Liu, R. An, , X. S. Xie

The paper identifies a potent and broad sarbecovirus-neutralizing antibody cocktail, SA55+SA58, from SARS convalescents to combat Omicron variants and other fast-evolving viruses.

bioRxiv · Aug 3, 2022Immunology

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Y. R. Cao, A. Yisimayi, F. Jian, W. Song, T. Xiao, L. Wang, S. Du, J. Wang, Q. Li, X. Chen, Y. Yu, P. Wang, Z. Zhang, P. Liu, R. An, , X. S. Xie

This study investigates antibody evasion by SARS-CoV-2 Omicron sublineages BA.2.12.1, BA.4, and BA.5 against plasma from vaccination and BA.1 infection, showing increased neutralization escape.

bioRxiv · Apr 30, 2022Immunology

Structural and functional characterizations of altered infectivity and immune evasion of SARS-CoV-2 Omicron variant

Z. Cui, P. Liu, N. Wang, L. Wang, K. Fan, Q. Zhu, K. Wang, R. Chen, R. Feng, Z. Jia, M. Yang, B. Zhu, W. Fu, T. Chu, L. Feng, , X. Wang

The paper characterizes structural and functional changes in the SARS-CoV-2 Omicron variant's Spike protein, identifying new immune escape sites and providing insights for vaccine development.

bioRxiv · Dec 29, 2021 · PreprintBiophysics

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Y. R. Cao, J. Wang, F. Jian, T. Xiao, W. Song, A. Yisimayi, W. Huang, Q. Li, P. Wang, R. An, J. Wang, Y. Wang, X. Niu, S. Yang, H. Liang, , X. S. Xie

This study identifies how Omicron evades neutralizing antibodies by analyzing mutations and their effects on different epitope groups, showing over 85% of tested antibodies are escaped.

bioRxiv · Dec 7, 2021Immunology

Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants

S. Du, P. Liu, Z. Zhang, T. Xiao, A. Yasimayi, W. Huang, Y. Wang, Y. R. Cao, X. S. Xie, J. Xiao

This study identifies two potent monoclonal antibodies against the B.1.351 variant and shows their efficacy against other variants, suggesting their use as an antibody cocktail.

bioRxiv · Jul 30, 2021Biochemistry